Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(51 sites)

United States

University of Alabama_6th Ave, Birmingham, Alabama

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber / Harvard Cancer Center, Boston, Massachusetts

Mayo Clinic - Rochester, Rochester, Minnesota

Roswell Park Cancer Institute, Buffalo, New York